Dr. Mann on Immunotherapy Developments in Prostate Cancer – OncLive
|
Dr. Mann on Immunotherapy Developments in Prostate Cancer
OncLive Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the future of immunotherapy in prostate cancer. According to Mann, sipuleucel-T (Provenge) was far ahead of the curve when it was first developed … |
